Navigation Links
Xlumena Announces Initial Commercial Use of its First-in-Class AXIOS Stent and Delivery System for Treatment of Pancreatic Pseudocysts and Fluid Collections

MOUNTAIN VIEW, Calif., Jan. 9, 2014 /PRNewswire/ -- Xlumena, Inc., a leader in advanced endoscopic devices, today announced the first US commercial use of its AXIOS Stent and Delivery System (AXIOS) at California Pacific Medical Center (CPMC) in San Francisco.  The recent FDA clearance of AXIOS represents a significant breakthrough in the treatment of patients with pancreatic pseudocysts and fluid collections.

There are more than 90,000 cases of pseudocysts and pancreatic fluid collections in the US each year and the global market is estimated to be greater than $200 million annually.  Prior to the FDA clearance of AXIOS last month, physicians had no "on-label" options for treating these conditions.  According to Christy Foreman, director of the Office of Device Evaluation at the FDA, "the AXIOS Stent provides a new option for physicians to effectively treat pseudocysts."

AXIOS is the first stent specifically designed for treatment of a pancreatic pseudocyst or fluid collection.   Its design allows for rapid drainage of these fluid collections, which are often filled with thick, infected or necrotic content.

"I'm delighted that we now have an anastomotic stent that was designed specifically for drainage of pancreatic fluid collections," said Dr. Kenneth Binmoeller, Founder and Chief Medical Officer of Xlumena.   Following FDA clearance of AXIOS, Dr. Binmoeller performed the first drainage of a pancreatic pseudocyst with AXIOS at CPMC.  "After AXIOS placement, we were able to clear out debris from the cyst with the endoscope, which led to immediate improvement of the patient's clinical course."  

Having just closed a $25M Series C financing, Xlumena is expanding to meet the demand for AXIOS, initiating a targeted launch in selected centers of excellence across the US. AXIOS is the first in a family of devices that Xlumena plans to bring to the US market to address significant clinical needs in the field of interventional endoscopy.  Already CE marked and used in rapidly growing numbers is the next-generation HOT AXIOS, which incorporates cautery into the delivery of the AXIOS stent and is currently used in Europe for the treatment of pancreatic pseudocysts, acute cholecystitis and biliary obstruction.

CAUTION: The HOT AXIOS and AXIOS devices for the gallbladder and bile duct have CE mark designation in Europe. They are not available for sale in the United States. 

For more information about the AXIOS Stent and Delivery System, please visit

About Xlumena, Inc.: Xlumena is the leader in developing products that enable advanced, image-guided endoscopy procedures. These innovations will allow endoscopists to offer minimally invasive alternatives to patients suffering from common gastrointestinal and biliary conditions. Pioneering interventional endoscopists around the world are using Xlumena's products to extend their therapeutic reach. 

Video with caption: "AXIOS Stent and Delivery System Procedure Animation". Video available at:

Joni Cronin

SOURCE Xlumena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xlumena Closes Series C Financing; Focuses on Expanding Global Commercial Presence and Obtaining FDA Clearance
2. EndoChoice Announces Investigator-Initiated Study Program for Fuse Endoscopy System
3. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
4. Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimers Disease
5. Endo Announces Divestiture Of HealthTronics
6. The MED Group Announces Agreement with Golden Technologies
7. BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma
8. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
9. Navigating Cancer Announces Milestones Related to Patient Education Program
10. TRICAST Announces Patent-Pending Technology for Real-Time Health Data Analysis
11. Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
Breaking Medicine News(10 mins):